FDA WARNING_LETTER - Philips Medical Systems, Inc

This FDA Warning Letter to Philips Medical Systems, Inc. details significant violations of the Quality System (QS) regulation (21 CFR Part 820) and Medical Device Reporting (MDR) regulations (21 CFR Part 803, 806) for their Computed Tomography (CT) and Nuclear Imaging Systems, rendering the devices adulterated and misbranded.

Inspections in July-September and October-November 2007 in Cleveland, Ohio, revealed multiple deficiencies. Key violations include:

* **Failure to establish and maintain adequate procedures for analyzing quality data and investigating nonconformities (21 CFR 820.100(a))**: This included 1,216 unprioritized software defects and 234 "showstopper" defects remaining open, and inconsistent opening of defect reports. While Philips' responses indicated corrective actions like defect review, database enhancements, and a new "Defect Management Policy," full adequacy will be assessed in future inspections. * **Inadequate complaint handling procedures for MDR reportability (21 CFR 820.198(a)(3))**: Procedures only required documented MDR assessment for "potential safety events," leading to only 7 out of 459 complaints having such assessments. Philips' revised procedure was deemed inadequate as it used a formulaic statement instead of requiring systematic evaluation. * **Failure to adequately establish and maintain complaint handling